WBB Securities Initiates Coverage on enGene (NASDAQ:ENGN)

Key Points

• WBB Securities initiated coverage on enGene (NASDAQ:ENGN) with a Buy rating and a $21.50 price target—implying about a 195% upside—and the stock carries a consensus Moderate Buy rating with an average target of $22.69 from multiple analysts.
• Shares trade near $7.29 (market cap ≈ $488M) while the company remains unprofitable (negative P/E and expected 2026 EPS of -1.56) despite a recent quarterly beat, and institutional investors own roughly 64% of the stock with sizable new stakes including a large position by Braidwell.

Analysts at WBB Securities initiated coverage on shares of enGene (NASDAQ:ENGN - Get Free Report) in a report issued on Monday, Marketbeat.com reports. The brokerage set a "buy" rating and a $21.50 price target on the stock. WBB Securities' price target would suggest a potential upside of 194.97% from the company's current price.

Other equities analysts have also issued reports about the company. HC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of enGene in a research report on Monday, March 9th. Guggenheim reissued a "buy" rating on shares of enGene in a research report on Tuesday, March 10th. Oppenheimer reduced their price target on enGene from $33.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 11th. Raymond James Financial reissued a "strong-buy" rating and set a $27.00 price target on shares of enGene in a research report on Monday, March 9th. Finally, Citigroup reissued a "market outperform" rating on shares of enGene in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $22.69.

enGene Price Performance

enGene stock traded up $0.09 during midday trading on Monday, reaching $7.29. 22,254 shares of the company were exchanged, compared to its average volume of 394,926. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.75 and a current ratio of 11.75. The company has a market capitalization of $488.29 million, a price-to-earnings ratio of -3.24 and a beta of -0.06. The firm's 50-day simple moving average is $8.39 and its 200-day simple moving average is $8.34. enGene has a 1 year low of $2.65 and a 1 year high of $12.25.

enGene (NASDAQ:ENGN - Get Free Report) last released its quarterly earnings data on Monday, March 9th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.11. On average, analysts anticipate that enGene will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ENGN. Cresset Asset Management LLC bought a new position in enGene during the 2nd quarter worth $36,000. Paloma Partners Management Co bought a new position in shares of enGene in the second quarter worth $38,000. PFS Partners LLC bought a new position in shares of enGene in the third quarter worth $61,000. Raymond James Financial Inc. grew its stake in shares of enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock worth $68,000 after purchasing an additional 7,932 shares in the last quarter. Finally, Braidwell LP bought a new position in shares of enGene in the third quarter worth $15,479,000. 64.16% of the stock is currently owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.